CRNX
Price
$37.35
Change
+$0.87 (+2.38%)
Updated
Jan 17 closing price
Capitalization
3.46B
59 days until earnings call
MRSN
Price
$0.62
Change
+$0.01 (+1.64%)
Updated
Jan 17 closing price
Capitalization
76.42M
39 days until earnings call
Ad is loading...

CRNX vs MRSN

Header iconCRNX vs MRSN Comparison
Open Charts CRNX vs MRSNBanner chart's image
Crinetics Pharmaceuticals
Price$37.35
Change+$0.87 (+2.38%)
Volume$761.82K
Capitalization3.46B
Mersana Therapeutics
Price$0.62
Change+$0.01 (+1.64%)
Volume$7.7M
Capitalization76.42M
CRNX vs MRSN Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. MRSN commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and MRSN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (CRNX: $37.35 vs. MRSN: $0.62)
Brand notoriety: CRNX and MRSN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 91% vs. MRSN: 194%
Market capitalization -- CRNX: $3.46B vs. MRSN: $76.42M
CRNX [@Biotechnology] is valued at $3.46B. MRSN’s [@Biotechnology] market capitalization is $76.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileMRSN’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • MRSN’s FA Score: 0 green, 5 red.
According to our system of comparison, CRNX is a better buy in the long-term than MRSN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while MRSN’s TA Score has 1 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 3 bearish.
  • MRSN’s TA Score: 1 bullish, 3 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than MRSN.

Price Growth

CRNX (@Biotechnology) experienced а -7.98% price change this week, while MRSN (@Biotechnology) price change was -14.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CRNX is expected to report earnings on May 08, 2025.

MRSN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.46B) has a higher market cap than MRSN($76.4M). CRNX YTD gains are higher at: -26.951 vs. MRSN (-56.741). MRSN has higher annual earnings (EBITDA): -68.51M vs. CRNX (-304.51M). CRNX has more cash in the bank: 863M vs. MRSN (155M). MRSN has less debt than CRNX: MRSN (31.5M) vs CRNX (52.5M). MRSN has higher revenues than CRNX: MRSN (34.8M) vs CRNX (1.04M).
CRNXMRSNCRNX / MRSN
Capitalization3.46B76.4M4,534%
EBITDA-304.51M-68.51M444%
Gain YTD-26.951-56.74147%
P/E RatioN/AN/A-
Revenue1.04M34.8M3%
Total Cash863M155M557%
Total Debt52.5M31.5M167%
FUNDAMENTALS RATINGS
CRNX vs MRSN: Fundamental Ratings
CRNX
MRSN
OUTLOOK RATING
1..100
6151
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
49100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
9298
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (90) in the Pharmaceuticals Major industry is in the same range as MRSN (91) in the Biotechnology industry. This means that CRNX’s stock grew similarly to MRSN’s over the last 12 months.

CRNX's Profit vs Risk Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRSN (100) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than MRSN’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as MRSN (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to MRSN’s over the last 12 months.

CRNX's Price Growth Rating (92) in the Pharmaceuticals Major industry is in the same range as MRSN (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to MRSN’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MRSN (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to MRSN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXMRSN
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
82%
N/A
Momentum
ODDS (%)
Bearish Trend 11 days ago
79%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
78%
Bearish Trend 11 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
76%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 13 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPEGX22.790.34
+1.51%
Morgan Stanley Inst Discovery I
ICEQX22.230.21
+0.95%
Macquarie Core Equity Fund Class R6
RICAX58.230.51
+0.88%
American Funds Invmt Co of Amer R1
TFSCX15.840.10
+0.64%
Templeton Ins Foreign Smaller Co Ser Adv
APSLX16.960.04
+0.24%
NYLI Fiera SMID Growth Class C

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with MRSN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then MRSN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+2.38%
MRSN - CRNX
49%
Loosely correlated
+0.68%
ELVN - CRNX
48%
Loosely correlated
-2.36%
ARWR - CRNX
48%
Loosely correlated
+2.84%
TRDA - CRNX
46%
Loosely correlated
+1.20%
DYN - CRNX
46%
Loosely correlated
-4.33%
More